Hevicain Spinal Tung (Bupivacaine Hydrochloride)

Hevicain Spinal Tung is indicated for use when a rapid, reliable spinal block is required.

• Spinal anesthesia for lower abdominal, pelvic, or lower limb surgical procedures.
• Obstetric analgesia during labor and delivery, including cesarean section.
• Intrathecal nerve block for postoperative pain management.
• Adjunct to general anesthesia to reduce intra‑operative opioid requirements.
• Diagnostic spinal procedures where temporary sensory blockade is needed.
• Use in combination with epidural techniques for extended analgesia in major surgeries.

• Bupivacaine hydrochloride exerts its anesthetic effect by binding to the intracellular portion of voltage‑gated sodium channels on neuronal membranes. This binding stabilizes the channel in an inactive state, preventing the influx of sodium ions during depolarization. As a result, the generation and propagation of action potentials along sensory and motor nerves are blocked, producing a reversible loss of sensation and muscle tone in the targeted spinal segment.

Adverse reactions to Hevicain Spinal Tung are reported in clinical practice and can vary in frequency and severity.

Common

• Transient hypotension or bradycardia that usually resolves with fluids.
• Pruritus or mild rash at the injection site, often self‑limiting.
• Nausea, vomiting, or dizziness shortly after injection.
• Temporary motor weakness or sensory loss lasting a few hours.
• Headache or lumbar discomfort within 24 hours post‑procedure.
• Transient visual disturbances such as blurred vision.

Serious

• Prolonged or high spinal block causing respiratory depression.
• Cardiac arrhythmias or arrest requiring resuscitation.
• CNS toxicity presenting as seizures, confusion, or loss of consciousness.
• Persistent neurological deficit such as prolonged numbness.
• Allergic anaphylactic reaction with urticaria, bronchospasm, or hypotension.

When using Hevicain Spinal Tung, clinicians should observe specific precautions to minimize risks and ensure patient safety.

• Verify patient identity and confirm the indication for intrathecal anesthesia before preparation.
• Assess cardiovascular status, including blood pressure and heart rate, as bupivacaine can cause hypotension and bradycardia.
• Perform a test dose when appropriate to detect inadvertent intravascular injection.
• Avoid use in patients with known hypersensitivity to amide‑type local anesthetics.
• Monitor respiratory function continuously during and after the block, especially in high spinal levels.
• Document the exact dose, concentration, and injection site in the medical record.

Hevicain Spinal Tung may interact with other agents that influence cardiac conduction, central nervous system activity, or local anesthetic metabolism.

Avoid

• Concurrent use of other long‑acting local anesthetics, which can increase the risk of systemic toxicity.
• Co‑administration with potent sodium channel blockers such as certain antiarrhythmic drugs.
• Avoid simultaneous administration of vasopressors that may mask hypotension signs.

Use with caution

• Concurrent opioids or sedatives, as they may enhance respiratory depression.
• Beta‑blockers or calcium channel blockers, which can potentiate bradycardia and hypotension.
• Diuretics that may alter plasma protein binding of bupivacaine.
• Anticonvulsants, because overlapping CNS depressant effects may occur.